CC
LYRA

Clearline Capital’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Clearline Capital’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,383
Closed -$33K – 156
2024
Q2 		$33K Hold
2,383
– – ﹤0.01% 144
2024
Q1 		$741K Hold
2,383
– – 0.04% 109
2023
Q4 		$624K Hold
2,383
– – 0.04% 89
2023
Q3 		$466K Hold
2,383
– – 0.04% 114
2023
Q2 		$490K Hold
2,383
– – 0.03% 102
2023
Q1 		$239K Hold
2,383
– – 0.04% 100
2022
Q4 		$374K Hold
2,383
– – 0.07% 104
2022
Q3 		$597K Hold
2,383
– – 0.07% 113
2022
Q2 		$673K Sell
2,383
-15
-0.6% -$4.08K 0.09% 104
2022
Q1 		$482K Buy
2,398
+1,101
+85% +$242K 0.06% 105
2021
Q4 		$283K Buy
+1,297
New +$417K 0.03% 123

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital's LYRA Position: Q3 2024 in Review

Clearline Capital sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2024, closing a stake of 2,383 shares — an estimated $33K sold.

Clearline Capital first reported a position in LYRA in Q4 2021 and held it in 11 quarters. The position peaked at $741K in Q1 2024. 62 funds tracked by Wall St. Rank hold LYRA as of Q3 2024.

  • Clearline Capital reported no remaining LYRA THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Clearline Capital sold 2,383 LYRA THERAPEUTICS INC shares in Q3 2024, an estimated $33K.
  • Clearline Capital first reported a position in LYRA THERAPEUTICS INC in Q4 2021 and held it in 11 quarters.
  • Clearline Capital's LYRA THERAPEUTICS INC position peaked at $741K in Q1 2024.
  • 62 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2024.

Based on Clearline Capital's 13F filing for Q3 2024, filed 14 Nov 2024.